Assenagon Asset Management S.A. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Assenagon Asset Management S.A. bought a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 341,800 shares of the biopharmaceutical company’s stock, valued at approximately $2,505,000. Assenagon Asset Management S.A. owned approximately 0.21% of Ocular Therapeutix as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Rhumbline Advisers lifted its holdings in Ocular Therapeutix by 2.7% during the 4th quarter. Rhumbline Advisers now owns 213,601 shares of the biopharmaceutical company’s stock worth $1,824,000 after buying an additional 5,682 shares during the last quarter. Palumbo Wealth Management LLC bought a new position in shares of Ocular Therapeutix in the 4th quarter worth about $100,000. Truist Financial Corp acquired a new position in Ocular Therapeutix in the fourth quarter valued at approximately $427,000. New York State Common Retirement Fund grew its stake in Ocular Therapeutix by 18.4% during the 4th quarter. New York State Common Retirement Fund now owns 98,097 shares of the biopharmaceutical company’s stock worth $838,000 after buying an additional 15,239 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. bought a new position in shares of Ocular Therapeutix during the fourth quarter worth about $897,000. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Price Performance

NASDAQ OCUL opened at $8.75 on Tuesday. The stock has a 50-day simple moving average of $7.76 and a 200 day simple moving average of $7.85. Ocular Therapeutix, Inc. has a twelve month low of $5.34 and a twelve month high of $11.78. The stock has a market capitalization of $1.39 billion, a PE ratio of -6.63 and a beta of 1.42. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Analyst Upgrades and Downgrades

Several analysts recently commented on OCUL shares. Royal Bank of Canada began coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 target price on the stock. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research report on Tuesday, March 4th. William Blair began coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an “outperform” rating on the stock. Needham & Company LLC reduced their price target on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Thursday, May 29th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.25.

Insider Transactions at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,219 shares of the stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total value of $152,352.42. Following the completion of the transaction, the insider now owns 3,499,099 shares in the company, valued at approximately $25,123,530.82. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard L. Md Lindstrom bought 10,000 shares of the firm’s stock in a transaction dated Thursday, May 8th. The shares were acquired at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares in the company, valued at $1,202,019.84. This represents a 6.15% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 29,079 shares of company stock worth $208,739 over the last three months. 2.30% of the stock is currently owned by insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.